Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Letter to the Editor: comment on the contradiction and standardization of the study.
    • Chi-Jen Hsu, doctor Department of Orthopedics, The Fifth Affiliated Hospital of Sun Yat-sen University, Guangdong, China
    • Other Contributors:
      • Mei Na Fok, doctor
      • Peilun Xiao, doctor
      • Chia-Chien Hsu, doctor
      • James Cheng-Chung Wei, doctor

    We have some comments on the retrospective study that looked at risk factors for severe COVID-19 in people with axial spondyloarthritis (axSpA), psoriasis (PsO), and psoriatic arthritis (PsA).1

    First, according to the findings of the study, the use of tumor necrosis factor (TNF) inhibitors was associated with decreased probabilities of severe COVID-19 outcomes. The author cites some previous studies using clinical database analysis to support the result. However, in recent research, Rebecca H Haberman et al obtained postvaccination blood samples from participants with immune-mediated inflammatory diseases and healthy controls and analyzed SARS-CoV-2-spike-specific antibody titers and neutralization capacity. Their results showed that TNF inhibitors might lead to a dampened humoral response to COVID-19 vaccinations, and the persistence of an adequate humoral response is significantly decreased by month 6. This finding supports the use of supplemental booster dosing in patients with immune-mediated inflammatory diseases, specifically for those being treated with TNF inhibitors. Larger basic research is required to clarify these contradictions and evaluate the impact of other immunomodulatory strategies, which will assist in determining the appropriate timing and method for COVID-19 vaccinations. 2

    Second, based on the results of one sensitivity analysis, Janus kinase (JAK) inhibitor use was associated with a higher risk of death owing to COVID-19 (binary outco...

    Show More
    Conflict of Interest:
    None declared.